$0.33 EPS Expected for Supernus Pharmaceuticals (SUPN) This Quarter

Analysts predict that Supernus Pharmaceuticals (NASDAQ:SUPN) will post earnings per share of $0.33 for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Supernus Pharmaceuticals’ earnings. The highest EPS estimate is $0.45 and the lowest is $0.26. Supernus Pharmaceuticals posted earnings per share of $0.19 during the same quarter last year, which would indicate a positive year-over-year growth rate of 73.7%. The company is scheduled to report its next earnings results on Tuesday, May 8th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year earnings of $1.85 per share for the current year, with EPS estimates ranging from $1.76 to $1.98. For the next fiscal year, analysts forecast that the company will report earnings of $2.64 per share, with EPS estimates ranging from $2.31 to $3.05. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that follow Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.18. The firm had revenue of $88.44 million during the quarter, compared to analyst estimates of $87.84 million. Supernus Pharmaceuticals had a return on equity of 28.07% and a net margin of 18.95%.



A number of brokerages have commented on SUPN. B. Riley reissued a “buy” rating and set a $54.00 price objective on shares of Supernus Pharmaceuticals in a report on Thursday, January 18th. BidaskClub raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 21st. Zacks Investment Research lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Berenberg Bank started coverage on Supernus Pharmaceuticals in a research note on Thursday, February 1st. They issued a “buy” rating and a $66.00 target price on the stock. Finally, ValuEngine upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $51.36.

In other news, VP Victor Vaughn sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, April 5th. The stock was sold at an average price of $45.33, for a total value of $2,719,800.00. Following the transaction, the vice president now owns 24,344 shares in the company, valued at approximately $1,103,513.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $44.98, for a total value of $899,600.00. Following the completion of the transaction, the vice president now owns 32,500 shares in the company, valued at approximately $1,461,850. The disclosure for this sale can be found here. Insiders sold a total of 100,000 shares of company stock worth $4,580,200 in the last 90 days. Company insiders own 6.70% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC bought a new stake in Supernus Pharmaceuticals during the 3rd quarter valued at $10,646,000. Stephens Investment Management Group LLC purchased a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $7,316,000. Wells Fargo & Company MN boosted its position in Supernus Pharmaceuticals by 22.7% during the fourth quarter. Wells Fargo & Company MN now owns 755,422 shares of the specialty pharmaceutical company’s stock valued at $30,105,000 after buying an additional 139,838 shares during the period. BlackRock Inc. boosted its position in Supernus Pharmaceuticals by 1.8% during the fourth quarter. BlackRock Inc. now owns 6,902,230 shares of the specialty pharmaceutical company’s stock valued at $275,054,000 after buying an additional 120,394 shares during the period. Finally, Rice Hall James & Associates LLC boosted its position in Supernus Pharmaceuticals by 8.0% during the fourth quarter. Rice Hall James & Associates LLC now owns 1,322,614 shares of the specialty pharmaceutical company’s stock valued at $52,706,000 after buying an additional 98,297 shares during the period. Institutional investors and hedge funds own 96.30% of the company’s stock.

SUPN traded down $0.80 during midday trading on Friday, reaching $45.25. 398,925 shares of the company were exchanged, compared to its average volume of 684,803. The firm has a market capitalization of $2,352.67, a P/E ratio of 35.91 and a beta of 1.11. Supernus Pharmaceuticals has a one year low of $29.95 and a one year high of $50.04.

ILLEGAL ACTIVITY WARNING: “$0.33 EPS Expected for Supernus Pharmaceuticals (SUPN) This Quarter” was reported by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://dakotafinancialnews.com/2018/04/13/0-33-eps-expected-for-supernus-pharmaceuticals-supn-this-quarter.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply